<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 5, 2018 (HealthDay News) — Recommendations have been developed by the World Health Organization for treatment intensification in type 2 diabetes. The recommendations were published online Sept. 4 in the Annals of Internal Medicine<\/i>.<\/p>\n
Gojka Roglic, M.D., and Susan L. Norris, M.D., M.P.H., from the World Health Organization in Switzerland, developed recommendations to provide guidance on medicine selection for treatment intensification in type 2 diabetes, and use of insulin in type 1 and 2 diabetes.<\/p>\n
The researchers developed five recommendations. One, a sulfonylurea should be given to patients with type 2 diabetes who do not achieve glycemic control with metformin alone or who have contraindications to metformin. Two, human insulin treatment should be introduced to patients with type 2 diabetes who do not achieve glycemic control with metformin and\/or a sulfonylurea. Three, a dipeptidyl peptidase-4 inhibitor, a sodium-glucose contransporter-2 inhibitor, or a thiazolidinedione may be added if insulin is unsuitable. Four, in adults with type 1 diabetes, and in adults with type 2 diabetes for whom insulin is indicated, human insulin should be used to manage blood glucose. Five, long-acting insulin analogues should be considered to manage blood glucose in adults with type 1 or type 2 diabetes who have frequent, severe hypoglycemia with human insulin.<\/p>\n
“The decision to name sulfonylureas as the single best second-line agent largely reflects the prioritization of cost and the recognition that WHO guidelines must apply to low-resource settings,” write the authors of an accompanying editorial.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n